Mosunetuzumab for treating relapsed or refractory follicular lymphoma

2.1 Mosunetuzumab (Lunsumio, Roche) is indicated for 'the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies'.

2.2 The dosage schedule is available in the summary of product characteristics for mosunetuzumab.

2.3 Mosunetuzumab costs £220 per 1 mg/1 ml concentrate for solution for infusion vial and £6,600 per 30 mg/30 ml concentrate for solution for infusion vial (excluding VAT; company submission). The cost per course of treatment is £66,660 for 8 cycles and £126,600 for 17 cycles.

2.4 The company has a commercial arrangement, which would have applied if mosunetuzumab had been recommended.